Denali Therapeutics, Inc.
(NASDAQ : DNLI)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 0.66%188.080.0%$913.39m
AMGNAmgen, Inc. 0.09%246.461.5%$592.53m
NVAXNovavax, Inc. 2.71%61.9075.7%$474.31m
VRTXVertex Pharmaceuticals, Inc. 0.39%289.151.9%$421.50m
GILDGilead Sciences, Inc. 0.39%61.331.0%$373.75m
REGNRegeneron Pharmaceuticals, Inc. 2.53%629.142.6%$353.17m
SNSSSunesis Pharmaceuticals, Inc. 1.03%3.910.7%$273.32m
ILMNIllumina, Inc. 1.93%228.093.3%$246.19m
BIIBBiogen, Inc. 1.65%221.811.8%$204.56m
GOVXGeoVax Labs, Inc. -4.99%3.060.0%$152.44m
BNTXBioNTech SE -8.62%167.330.0%$140.10m
CRSPCRISPR Therapeutics AG 1.78%82.850.6%$135.13m
RYTMRhythm Pharmaceuticals, Inc. 19.57%24.200.0%$109.16m
MRTXMirati Therapeutics, Inc. 6.61%92.281.6%$99.70m
BMRNBioMarin Pharmaceutical, Inc. 0.94%96.724.2%$96.23m

Company Profile

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.